Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
about
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewNovel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamsterStatins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link.Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study.Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE studyHypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.Association and interaction of PPARα, δ, and γ gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han populationBezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trialPPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose ToleranceRoles of Vitamin A Metabolism in the Development of Hepatic Insulin Resistance.Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonistsRefocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.Cardiometabolic impact of non-statin lipid lowering therapies.Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.The diabetogenic action of statins - mechanisms and clinical implications.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease.Dyslipidemia in patients with chronic kidney disease.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.PPAR-γ agonist attenuates inflammation in aortic aneurysm patients.Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.Fibrates in the management of atherogenic dyslipidemia.An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors.PPAR Agonists and Metabolic Syndrome: An Established Role?β-Cell Failure or β-Cell Abuse?
P2860
Q24561401-75ED335E-D001-4862-BD44-616822F8EC33Q28538170-266DD285-7EE8-42E0-979D-20F1FD5E0D5CQ33790331-E0D3C8E0-A19C-4356-8547-BA3F0395DB41Q33808884-45E54956-27BB-42E6-A1D7-F2A2D775154FQ33938898-67786369-45EF-4FBE-AFA2-1CCFC7EAC782Q34067485-C5AFCF7D-E943-48F9-B00E-DE35BDF838EAQ34422821-8488B7B4-D0E8-42DD-AB64-0FD5C8FEA9D5Q34481529-401D2B81-A285-4926-A9CA-F7C01882EA90Q34687470-C957DF22-AD78-4DFC-A389-A8DA8066AF8DQ35865309-3F56B3D0-4BCF-4982-B8EB-ACB78DE55019Q36489752-C649FB52-8D2E-45C3-B5E2-1281B6A3B8CFQ36681266-69DD3694-F1D5-4B1E-8E19-A1A44036F5E7Q36962066-FFDD4CFC-13B8-4ACC-A885-3D9DBCBC161EQ37626226-915B7359-D7FA-4DBB-A836-2650922CF2D7Q38110581-3090D04B-1BF1-47D5-AE95-F5638644A8A7Q38160494-7E185825-E392-41F7-9FFB-72F2D40F9D0AQ38176275-CC697BF0-466C-40A0-A75D-AA87462EBC5DQ38222135-CF1601D0-AF11-4F60-9064-E7826DC4BF8BQ38546242-853461EE-C76D-4460-A90D-4D54D85A60EDQ38669513-44F6BCF2-9CA0-4B5C-9543-B75F25C70FFFQ38674742-95F13C30-12C6-44E4-BEDE-EB087663A232Q38817895-D7850E2E-9D3B-4742-B7E4-37F236570BC0Q39045120-BD756D9E-DDA7-44E9-AA9E-A0A4292CB3DAQ39145017-67DB274D-AEA5-4B2F-806C-7334AF3CDA0DQ40693751-DDDEC234-8CE8-4107-979C-EAC63E1B936EQ46945180-66E107AE-DBB7-43C8-92B9-83C784FEDF3DQ49571281-EDFA79DB-F166-4F74-9A2D-0A26FF1C0775Q53684513-35B9F27E-8C91-42FF-B4D6-71DB1DA4A868Q54936265-082C5793-50F3-4072-8012-212312B17F0FQ57075124-D70310F3-FF8A-42E4-B3B7-E9756A71F66E
P2860
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@ast
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@en
type
label
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@ast
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@en
prefLabel
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@ast
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@en
P2860
P921
P356
P1476
Balanced pan-PPAR activator be ...... ntrol and diabetes prevention?
@en
P2093
Alexander Tenenbaum
Enrique Z Fisman
P2860
P2888
P356
10.1186/1475-2840-11-140
P407
P5008
P577
2012-11-14T00:00:00Z
P5875
P6179
1037896621